AstraZeneca's Price Target Raised to $97 by Berenberg Analysts
ByAinvest
Wednesday, Jul 9, 2025 10:18 pm ET1min read
AZN--
The analyst highlighted that AstraZeneca's shares should reflect a larger pipeline valuation, indicating that the company's ongoing advancements in its drug portfolio are being undervalued. The updated revenue forecast underscores the analyst's confidence in AstraZeneca's ability to deliver strong financial performance over the next decade.
AstraZeneca's shares have been trading at around $70.82, and the current analyst consensus price target stands at $84.18, with a high of $97.00. The company's earnings per share (EPS) estimates for the current quarter are expected to be $1.13, with a range of $1.07 to $1.20 [2].
The recent price target increase comes amidst a broader market focus on AstraZeneca's strategic moves, including potential deals and market expansions. The company has been exploring a deal with Summit Therapeutics, which could add significant value to its oncology portfolio, and rumors about a U.S. stock listing are also circulating [3].
Investors should closely monitor AstraZeneca's pipeline progress and the potential outcomes of these strategic initiatives. The company's strong dividend history and relatively low valuation compared to peers like Roche and Merck make it an attractive investment opportunity for long-term investors.
References:
[1] https://www.tipranks.com/news/the-fly/astrazeneca-price-target-raised-to-97-from-93-at-berenberg-thefly
[2] https://finance.yahoo.com/quote/AZN/analysis/
[3] https://www.ainvest.com/news/astrazeneca-dip-golden-buying-opportunity-oncology-innovation-2507/
MRK--
SMMT--
Berenberg analyst Luisa Hector raised AstraZeneca's price target to $97 from $93 and kept a Buy rating, citing substantial pipeline progress and increasing the 2030 revenue forecast by 3% to $79B, ahead of consensus. The analyst believes AstraZeneca shares should price in a larger pipeline valuation.
Berenberg analyst Luisa Hector recently raised AstraZeneca's (AZN) price target to $97 from $93, maintaining a Buy rating on the shares. The analyst cited substantial pipeline progress and increased the 2030 revenue forecast by 3% to $79 billion, surpassing consensus estimates [1].The analyst highlighted that AstraZeneca's shares should reflect a larger pipeline valuation, indicating that the company's ongoing advancements in its drug portfolio are being undervalued. The updated revenue forecast underscores the analyst's confidence in AstraZeneca's ability to deliver strong financial performance over the next decade.
AstraZeneca's shares have been trading at around $70.82, and the current analyst consensus price target stands at $84.18, with a high of $97.00. The company's earnings per share (EPS) estimates for the current quarter are expected to be $1.13, with a range of $1.07 to $1.20 [2].
The recent price target increase comes amidst a broader market focus on AstraZeneca's strategic moves, including potential deals and market expansions. The company has been exploring a deal with Summit Therapeutics, which could add significant value to its oncology portfolio, and rumors about a U.S. stock listing are also circulating [3].
Investors should closely monitor AstraZeneca's pipeline progress and the potential outcomes of these strategic initiatives. The company's strong dividend history and relatively low valuation compared to peers like Roche and Merck make it an attractive investment opportunity for long-term investors.
References:
[1] https://www.tipranks.com/news/the-fly/astrazeneca-price-target-raised-to-97-from-93-at-berenberg-thefly
[2] https://finance.yahoo.com/quote/AZN/analysis/
[3] https://www.ainvest.com/news/astrazeneca-dip-golden-buying-opportunity-oncology-innovation-2507/
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet